When patients present to your clinical practice with relapsed/refractory acute myeloid leukemia (R/R AML), do you have the confidence to take on the task of selecting and sequencing the optimal treatment regimen? Test your skills and gain expertise with this interactive case-based challenge, designed to help you synthesize the latest clinical evidence, disease factors, and patient preference to guide individualized treatment selection for R/R AML management.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/targeted-therapy-selection-sequencing-relapsed-refractory-aml
- Start Date: 2024-12-20 06:00:00
- End Date: 2024-12-20 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.25 hours
AMA PRA Category 1 Credit™️: 0.25 hours
Nursing: 0.25 hours
Pharmacy: 0.25 hours - MOC Credit Details: ABIM - 0.25 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Rigel Pharmaceuticals, Inc. - Amount: 16666.67 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Hematology, Medical Oncology
Subscribe
Login
0 Comments
Oldest